HY-0102
HY-0102 is a humanized IgG anti-NKG2A monoclonal antibody and immune checkpoint inhibitor targeting the NKG2A/HLA-E axis. HY-0102 is applicable for the research of advanced solid tumors.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Human
NKG2A/CD94
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. López-Botet M, et al. The CD94/NKG2A-HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective. Clin Cancer Res. 2026;32(6):1013-1019. [Content Brief]
[2]. Benitez Fuentes JD, et al. Association between human leukocyte antigen E expression and outcomes in solid tumors: a systematic review and meta-analysis. Front Oncol. 2025;15:1525924. Published 2025 Feb 24. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)